A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
NCT ID: NCT00134173
Last Updated: 2007-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1100 participants
INTERVENTIONAL
2003-10-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
torcetrapib/atorvastatin
atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid.
* Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
* Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Mobile, Alabama, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Los Altos, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Mountain View, California, United States
Pfizer Investigational Site
Sacramento, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
Santa Rosa, California, United States
Pfizer Investigational Site
Stockton, California, United States
Pfizer Investigational Site
Boulder, Colorado, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Brandford, Connecticut, United States
Pfizer Investigational Site
Farmington, Connecticut, United States
Pfizer Investigational Site
Guilford, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
Atlantis, Florida, United States
Pfizer Investigational Site
Clearwater, Florida, United States
Pfizer Investigational Site
Dunedin, Florida, United States
Pfizer Investigational Site
Fort Lauderdale, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Largo, Florida, United States
Pfizer Investigational Site
Melbourne, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Pensacola, Florida, United States
Pfizer Investigational Site
Safety Harbor, Florida, United States
Pfizer Investigational Site
Sarasota, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Blue Island, Illinois, United States
Pfizer Investigational Site
Merrionette Park, Illinois, United States
Pfizer Investigational Site
Rockford, Illinois, United States
Pfizer Investigational Site
Elkhart, Indiana, United States
Pfizer Investigational Site
Goshen, Indiana, United States
Pfizer Investigational Site
Hobart, Indiana, United States
Pfizer Investigational Site
Merrillville, Indiana, United States
Pfizer Investigational Site
Davenport, Iowa, United States
Pfizer Investigational Site
Des Moines, Iowa, United States
Pfizer Investigational Site
West Des Moines, Iowa, United States
Pfizer Investigational Site
Shawnee Mission, Kansas, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Bogalusa, Louisiana, United States
Pfizer Investigational Site
Covington, Louisiana, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
Auburn, Maine, United States
Pfizer Investigational Site
Lewiston, Maine, United States
Pfizer Investigational Site
Portland, Maine, United States
Pfizer Investigational Site
Scarborough, Maine, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Columbia, Maryland, United States
Pfizer Investigational Site
Salisbury, Maryland, United States
Pfizer Investigational Site
Takoma Park, Maryland, United States
Pfizer Investigational Site
Ann Arbor, Michigan, United States
Pfizer Investigational Site
Flint, Michigan, United States
Pfizer Investigational Site
Kalamazoo, Michigan, United States
Pfizer Investigational Site
Lapeer, Michigan, United States
Pfizer Investigational Site
Petoskey, Michigan, United States
Pfizer Investigational Site
Royal Oak, Michigan, United States
Pfizer Investigational Site
Saginaw, Michigan, United States
Pfizer Investigational Site
Ypsilanti, Michigan, United States
Pfizer Investigational Site
Duluth, Minnesota, United States
Pfizer Investigational Site
Maplewood, Minnesota, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Saint Cloud, Minnesota, United States
Pfizer Investigational Site
Saint Paul, Minnesota, United States
Pfizer Investigational Site
Southaven, Mississippi, United States
Pfizer Investigational Site
Kansas City, Missouri, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Ridgewood, New Jersey, United States
Pfizer Investigational Site
Albuquerque, New Mexico, United States
Pfizer Investigational Site
Carlsbad, New Mexico, United States
Pfizer Investigational Site
Albany, New York, United States
Pfizer Investigational Site
Bay Shore, New York, United States
Pfizer Investigational Site
Buffalo, New York, United States
Pfizer Investigational Site
Flushing, New York, United States
Pfizer Investigational Site
Johnson City, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Oneonta, New York, United States
Pfizer Investigational Site
Poughkeepsie, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Troy, New York, United States
Pfizer Investigational Site
Williamsville, New York, United States
Pfizer Investigational Site
Eden, North Carolina, United States
Pfizer Investigational Site
Greensboro, North Carolina, United States
Pfizer Investigational Site
Greenville, North Carolina, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Reidsville, North Carolina, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Bellevue, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Clyde, Ohio, United States
Pfizer Investigational Site
Defiance, Ohio, United States
Pfizer Investigational Site
Fostoria, Ohio, United States
Pfizer Investigational Site
Middleburg Heights, Ohio, United States
Pfizer Investigational Site
Orange, Ohio, United States
Pfizer Investigational Site
Toledo, Ohio, United States
Pfizer Investigational Site
Wauseon, Ohio, United States
Pfizer Investigational Site
Westlake, Ohio, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Eugene, Oregon, United States
Pfizer Investigational Site
Florence, Oregon, United States
Pfizer Investigational Site
Hillsboro, Oregon, United States
Pfizer Investigational Site
Doylestown, Pennsylvania, United States
Pfizer Investigational Site
Harrisburg, Pennsylvania, United States
Pfizer Investigational Site
Hershey, Pennsylvania, United States
Pfizer Investigational Site
Lancaster, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States
Pfizer Investigational Site
Wormleysburg, Pennsylvania, United States
Pfizer Investigational Site
Greenville, South Carolina, United States
Pfizer Investigational Site
Chattanooga, Tennessee, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Oak Ridge, Tennessee, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Annandale, Virginia, United States
Pfizer Investigational Site
Charlottesville, Virginia, United States
Pfizer Investigational Site
Falls Church, Virginia, United States
Pfizer Investigational Site
Norfolk, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Bellevue, Washington, United States
Pfizer Investigational Site
Seattle, Washington, United States
Pfizer Investigational Site
Huntington, West Virginia, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Aalst, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Genk, , Belgium
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Torono, Ontario, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Nijmegen, , Netherlands
Pfizer Investigational Site
Rotterdam, , Netherlands
Pfizer Investigational Site
Katowice, , Poland
Pfizer Investigational Site
Krakow, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
L´Hospitalet Del Llobregat, Barcelona, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Vigo, Pontevedra, Spain
Pfizer Investigational Site
Oviedo, Principality of Asturias, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008 Dec 9;118(24):2506-14. doi: 10.1161/CIRCULATIONAHA.108.790733. Epub 2008 Nov 24.
Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007 Mar 29;356(13):1304-16. doi: 10.1056/NEJMoa070635. Epub 2007 Mar 26.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5091005
Identifier Type: -
Identifier Source: org_study_id